Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Common Equity (2016 - 2017)

Historic Common Equity for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q3 2017 value amounting to $20.6 million.

  • Eledon Pharmaceuticals' Common Equity fell 3185.38% to $20.6 million in Q3 2017 from the same period last year, while for Sep 2017 it was $20.6 million, marking a year-over-year decrease of 3185.38%. This contributed to the annual value of -$2.7 million for FY2016, which is 10437.76% down from last year.
  • According to the latest figures from Q3 2017, Eledon Pharmaceuticals' Common Equity is $20.6 million, which was down 3185.38% from $23.4 million recorded in Q2 2017.
  • Over the past 5 years, Eledon Pharmaceuticals' Common Equity peaked at $103.5 million during Q4 2014, and registered a low of -$55.3 million during Q4 2013.
  • Its 5-year average for Common Equity is $45.9 million, with a median of $45.1 million in 2016.
  • In the last 5 years, Eledon Pharmaceuticals' Common Equity soared by 28727.45% in 2014 and then plummeted by 10437.76% in 2016.
  • Quarter analysis of 5 years shows Eledon Pharmaceuticals' Common Equity stood at -$55.3 million in 2013, then skyrocketed by 287.27% to $103.5 million in 2014, then tumbled by 40.36% to $61.7 million in 2015, then crashed by 104.38% to -$2.7 million in 2016, then surged by 863.1% to $20.6 million in 2017.
  • Its last three reported values are $20.6 million in Q3 2017, $23.4 million for Q2 2017, and $23.4 million during Q1 2017.